Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CA103T
- Development stage
- Preclinical
- Lead developer
- Curigin
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
- Administration
- Intratumoral, Oral, Intravenous, Intramuscular, Subcutaneous, Intraperitoneal
01
Overview
CA103T is an investigational oncolytic gene therapy being developed by Curigin for the treatment of advanced prostate cancer, specifically stage 4 prostate cancer. It consists of a genetically engineered oncolytic adenovirus vector designed to deliver a bi-specific short hairpin RNA (shRNA) payload that simultaneously targets and knocks down the expression of mammalian target of rapamycin (mTOR) and androgen receptor (AR) genes. By selectively replicating in cancer cells and silencing these two critical survival and growth pathways, CA103T aims to induce tumor cell death and stimulate an anti-tumor immune response.
- Other names
- CA 103CA103CA-103CA 103TCA103TCA-103T
02
Targets
mTOR (Mammalian target of rapamycin kinase)AR (Adrenergic receptors)
Beyond the preview
Go deeper on CA103T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CA103T.